Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Phase I Non-Myeloablative Trial With 90Y-Humanized MN-14 (Anti-CEA) Antibody for Relapsed or Refractory Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Listed as NCT00006458, this PHASE1 trial focuses on Lung Cancer and remains ongoing. Sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology, it has been updated 5 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
First recorded
Aug 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Belleville, United States